05/17/22 8:00 AMNasdaq : EQ conferenceslow floatEquillium to Present at Two Upcoming Investor ConferencesEquillium, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will be presenting at the H.C. Wainwright Global Investment Conference and the Jefferies Healthcare Conference. Management will provide a...RHEA-AIneutral
05/12/22 4:01 PMNasdaq : EQ earningsclinical triallow floatEquillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development UpdatesEquillium, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the first quarter 2022 and provided an update on its corporate development and clinical programs. “It’ s been a transformative start to...RHEA-AIneutral
05/12/22 8:00 AMNasdaq : EQ low floatEquillium Announces Publication of Abstract for the Annual Congress of the European Hematology AssociationEquillium, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that the European Hematology Association has published an abstract highlighting the Phase 3 EQUATOR study in first-line acute graft-versus-host...RHEA-AIneutral
05/09/22 8:00 AMNasdaq : EQ low floatEquillium Announces Three Poster Presentations at the Annual Meeting of The American Association of ImmunologistsEquillium, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that three posters were presented over the weekend at IMMUNOLOGY2022, the annual meeting of The American Association of Immunologists.RHEA-AIpositive
04/25/22 8:00 AMNasdaq : EQ low floatEquillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTREquillium, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that three posters were presented over the weekend at the Transplantation& Cellular Meetings of the American Society of Transplantation and Cellular...RHEA-AIneutral
04/04/22 8:00 AMNasdaq : EQ low floatEquillium Announces Oral Presentation at the Italian Society of Experimental HematologyEquillium, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced an oral presentation at the 2022 National Congress of the Italian Society of Experimental Hematology in Rome, Italy. The presentation analyzes data from the...RHEA-AIneutral
03/23/22 4:01 PMNasdaq : EQ earningsclinical triallow floatEquillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development UpdatesEquillium, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the fourth quarter and full year 2021 and provided corporate and clinical development updates. “I’ m proud of our team and the progress we...RHEA-AIneutral
03/23/22 8:00 AMNasdaq : EQ low floatEquillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow TransplantationEquillium, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced two oral presentations at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation. Clinical data were presented by Corey...RHEA-AIpositive
03/04/22 8:00 AMNasdaq : EQ clinical triallow floatEquillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host DiseaseEquillium, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced the initiation of the EQUATOR study, a pivotal Phase 3 clinical study of itolizumab in patients with acute graft-versus-host disease.RHEA-AIpositive
03/01/22 8:00 AMNasdaq : EQ managementlow floatEquillium Announces Appointment of Barbara Troupin to Board of DirectorsEquillium, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced the appointment of Barbara Troupin, M.D., to the Equillium Board of Directors. Barbara Troupin to the Equillium Board,” said Dan Bradbury, chairman of the board of...RHEA-AIneutral